Top Gene Interactions
- Metabolism: Half Life: The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
- Uses/Sources: Nalbuphine is indicated for the relief of moderate to severe pain. It can also be used as a supplement to balanced anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia during labor and delivery. [Wikipedia]
- Health Effects: Medical problems can include congested lungs, liver disease, tetanus, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose.
- Symptoms: Symptoms of overdose include primarily sleepiness and mild dysphoria.
- Treatment: The immediate intravenous administration an opiate antagonist such as naloxone or nalmefene is a specific antidote. Oxygen, intravenous fluids, vasopressors and other supportive measures should be used as indicated. (L1712)
- Route of Exposure: Intravenous. The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine.
- Carcinogenicity: No indication of carcinogenicity to humans (not listed by IARC).
- Toxicity: LD50: 1100 mg/kg (Oral, Dog) (A308)
Mechanism of Action
|Target Name||Mechanism of Action||References|
Mu-type opioid receptor
Kappa-type opioid receptor
Delta-type opioid receptor
|Receptor studies show that nalbuphine exerts its action via binding to mu, kappa, and delta receptors, but not to sigma receptors. Nalbuphine is primarily a kappa agonist/partial mu antagonist analgesic.||
Nalbuphine Interacts with Diseases
|Disease||Inference Score||References/Inference Genes|
|Substance Withdrawal Syndrome||5.63||
|Growth Hormone-Secreting Pituitary Adenoma||5.32||
|Epilepsy, Idiopathic Generalized||5.31||
|Pregnancy Complications, Cardiovascular||5.05||
|Leydig Cell Tumor||5.01||